Page 118 - Read Online

8. Mariani G, Bruselli L, Kuwert T, Kim EE, Flotats A, Israel O, Dondi M, 26. Go KG, Pruim J, Que TH, Vaalburg W, Haaxma‑Reiche H.
Watanabe N. A review on the clinical uses of SPECT/CT. Eur J Nucl Evaluation of dissemination studies with FDG whole‑body
Med Mol Imaging 2010;37:1959‑85. positron emission tomography in patients with suspected
9. Okajima K, Ohta Y. Diagnostic imaging of high‑grade astrocytoma: metastatic tumours of brain and spine. Acta Neurochir (Wien)
heterogeneity of clinical manifestation, image characteristics, and 2000;142:627‑31.
histopathological findings. Brain Nerve 2012;64:1151‑7. 27. Jeong HJ, Chung JK, Kim YK, Kim CY, Kim DG, Jeong JM, Lee DS,
10. Alexiou GA, Tsiouris S, Voulgaris S, Kyritsis AP, Fotopoulos AD. Jung HW, Lee MC. Usefulness of whole‑body (18)F‑FDG PET
Glioblastoma multiforme imaging: the role of nuclear medicine. in patients with suspected metastatic brain tumors. J Nucl Med
Curr Radiopharm 2012;5:308‑13. 2002;43:1432‑7.
11. Alexiou GA, Tsiouris S, Kyritsis AP, Fotakopoulos G, Goussia A, 28. Klee B, Law I, Højgaard L, Kosteljanetz M. Detection of
Voulgaris S, Fotopoulos AD. The value of 99mTc‑tetrofosmin unknown primary tumours in patients with cerebral metastases
brain SPECT in predicting survival in patients with glioblastoma using whole‑body 18F‑flouorodeoxyglucose positron emission
multiforme. J Nucl Med 2010;51:1923‑6. tomography. Eur J Neurol 2002;9:657‑62.
12. Colavolpe C, Chinot O, Metellus P, Mancini J, Barrie M, Bequet‑Boucard C, 29. Campos S, Davey P, Hird A, Pressnail B, Bilbao J, Aviv RI,
Tabouret E, Mundler O, Figarella‑Branger D, Guedj E. FDG‑PET predicts Symons S, Pirouzmand F, Sinclair E, Culleton S, Desa E, Goh P,
survival in recurrent high‑grade gliomas treated with bevacizumab and Chow E. Brain metastasis from an unknown primary, or primary
irinotecan. Neuro Oncol 2012;14:649‑57. brain tumour? A diagnostic dilemma. Curr Oncol 2009;16:62‑6.
13. Santra A, Kumar R, Sharma P, Bal C, Kumar A, Julka PK, Malhotra A. 30. Kyritsis AP, Levin VA, Yung WK, Leeds NE. Imaging patterns of
F‑18 FDG PET‑CT in patients with recurrent glioma: comparison multifocal gliomas. Eur J Radiol 1993;16:163‑70.
with contrast enhanced MRI. Eur J Radiol 2012;81:508‑13. 31. Hanson MW, Glantz MJ, Hoffman JM, Friedman AH, Burger PC,
14. Borbély K, Nyáry I, Tóth M, Ericson K, Gulyás B. Optimization Schold SC, Coleman RE. FDG‑PET in the selection of brain lesions
of semi‑quantification in metabolic PET studies with for biopsy. J Comput Assist Tomogr 1991;15:796‑801.
18F‑fluorodeoxyglucose and 11C‑methionine in the determination 32. Kawai N, Miyake K, Nishiyama Y, Yamamoto Y, Miki A, Haba R,
of malignancy of gliomas. J Neurol Sci 2006;246:85‑94. Imai T, Tamiya T, Nagao S. Targeting optimal biopsy location in
15. Singhal T, Narayanan TK, Jacobs MP, Bal C, Mantil JC basal ganglia germinoma using (11)C‑methionine positron emission
11C‑methionine PET for grading and prognostication in gliomas: tomography. Surg Neurol 2008;70:408‑13.
a comparison study with 18F‑FDG PET and contrast enhancement 33. Grosu AL, Piert M, Weber WA, Jeremic B, Picchio M,
on MRI. J Nucl Med 2012;53:1709‑15. Schratzenstaller U, Zimmermann FB, Schwaiger M, Molls M. Positron
16. Yamaguchi S, Terasaka S, Kobayashi H, Narita T, Hirata K, Shiga S, emission tomography for radiation treatment planning. Strahlenther
Usui R, Tanaka S, Kubota K, Murata J, Asaoka K. Combined use Onkol 2005;181:483‑99.
of positron emission tomography with (18)F‑fluorodeoxyglucose 34. Schaller B. Usefulness of positron emission tomography in
and (11)C‑methionine for preoperative evaluation of gliomas. No diagnosis and treatment follow‑up of brain tumors. Neurobiol Dis
Shinkei Geka 2010;38:621‑8. 2004;15:437‑48.
17. Tripathi M, Sharma R, D’Souza M, Jaimini A, Panwar P, Varshney R, 35. Santra A, Kumar R, Sharma P, Bal C, Julka PK, Malhotra A. F‑18
Datta A, Kumar N, Garg G, Singh D, Grover RK, Mishra AK, FDG PET‑CT for predicting survival in patients with recurrent glioma:
Mondal A. Comparative evaluation of F‑18 FDOPA, F‑18 FDG, a prospective study. Neuroradiology 2011;53:1017‑24.
and F‑18 FLT‑PET/CT for metabolic imaging of low grade gliomas. 36. Charnley N, West CM, Barnett CM, Brock C, Bydder GM, Glaser M,
Clin Nucl Med 2009;34:878‑83. Newlands ES, Swindell R, Matthews J, Price P. Early change in
18. Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, glucose metabolic rate measured using FDG‑PET in patients with
Liau L, Mischel P, Czernin J, Phelps ME, Silverman DH. Imaging high‑grade glioma predicts response to temozolomide but not
proliferation in brain tumors with 18F‑FLT PET: comparison with temozolomide plus radiotherapy. Int J Radiat Oncol Biol Phys
18F‑FDG. J Nucl Med 2005;46:945‑52. 2006;66:331‑8.
19. Enslow MS, Zollinger LV, Morton KA, Butterfield RI, Kadrmas DJ, 37. Bohndiek SE, Brindle KM. Imaging and ‘omic’ methods for
Christian PE, Boucher KM, Heilbrun ME, Jensen RL, Hoffman JM. the molecular diagnosis of cancer. Expert Rev Mol Diagn
Comparison of 18F‑fluorodeoxyglucose and 18F‑fluorothymidine 2010;10:417‑34.
PET in differentiating radiation necrosis from recurrent glioma. Clin 38. Alkonyi B, Barger GR, Mittal S, Muzik O, Chugani DC, Bahl G,
Nucl Med 2012;37:854‑61. Robinette NL, Kupsky WJ, Chakraborty PK, Juhász C. Accurate
20. Karunanithi S, Sharma P, Kumar A, Khangembam BC, differentiation of recurrent gliomas from radiation injury by
Bandopadhyaya GP, Kumar R, Gupta DK, Malhotra A, Bal C. kinetic analysis of a‑11C‑methyl‑L‑tryptophan PET. J Nucl Med
18F‑FDOPA PET/CT for detection of recurrence in patients with 2012;53:1058‑64.
glioma: prospective comparison with 18F‑FDG PET/CT. Eur J Nucl 39. Kumar A, Asano E, Chugani HT. A‑[¹¹C]‑methyl‑L‑tryptophan PET
Med Mol Imaging 2013;40:1025‑35. for tracer localization of epileptogenic brain regions: clinical studies.
21. Tripathi M, Sharma R, Varshney R, Jaimini A, Jain J, Souza MM, Biomark Med 2011;5:577‑84.
Bal J, Pandey S, Kumar N, Mishra AK, Mondal A. Comparison 40. Arbizu J, Tejada S, Marti‑Climent JM, Diez‑Valle R, Prieto E,
of F‑18 FDG and C‑11 methionine PET/CT for the evaluation of Quincoces G, Vigil C, Idoate MA, Zubieta JL, Peñuelas I, Richter JA.
recurrent primary brain tumors. Clin Nucl Med 2012;37:158‑63. Quantitative volumetric analysis of gliomas with sequential MRI and
22. Pötzi C, Becherer A, Marosi C, Karanikas G, Szabo M, ¹¹C‑methionine PET assessment: patterns of integration in therapy
Dudczak R, Kletter K, Asenbaum S. 11C methionine and [18F] planning. Eur J Nucl Med Mol Imaging 2012;39:771‑81.
fluorodeoxyglucose PET in the follow‑up of glioblastoma multiforme. 41. Bustany P, Chatel M, Derlon JM, Darcel F, Sgouropoulos P,
J Neurooncol 2007;84:305‑14. Soussaline F, Syrota A. Brain tumor protein synthesis and histological
23. Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for grades: a study by positron emission tomography (PET) with
recurrent glioma diagnosis: a meta‑analysis. AJNR Am J Neuroradiol C11‑L‑Methionine. J Neurooncol 1986;3:397‑404.
2013;34:944‑50, S1‑11. 42. Terakawa Y, Tsuyuguchi N, Iwai Y, Yamanaka K, Higashiyama S,
24. Raman A, Rothrock JF, Liu HG, Mountz JM. Differentiation of Takami T, Ohata K. Diagnostic accuracy of 11C‑methionine PET
benign vs. malignant mass in a postirradiation cerebral arteriovenous for differentiation of recurrent brain tumors from radiation necrosis
malformation by 2‑deoxy‑2‑[18F] fluoro‑D‑glucose positron after radiotherapy. J Nucl Med 2008;49:694‑9.
emission tomography. Mol Imaging Biol 2004;6:1‑6. 43. Galldiks N, Kracht LW, Burghaus L, Thomas A, Jacobs AH,
25. Polyzoidis KS, Miliaras G, Pavlidis N. Brain metastasis of unknown Heiss WD, Herholz K. Use of 11C‑methionine PET to monitor the
primary: a diagnostic and therapeutic dilemma. Cancer Treat Rev effects of temozolomide chemotherapy in malignant gliomas. Eur
2005;31:247‑55. J Nucl Med Mol Imaging 2006;33:516‑24.

112 Neuroimmunol Neuroinflammation | Volume 1 | Issue 3 | December 2014